3 April 2019 | Several health tech investors, including Health Innovation Fund III, invest in MedApp. MedApp develops a mobile platform that offers end users more control over their medication, which therefore improves their quality of life. MedApp accomplishes this by enabling end users to create a personal intake schedule, as well as reminding them when to take their medication, their inventory management and prescription refills at their own pharmacy. The investment will be used to further strengthen the position as market leader in the Netherlands and better integrate the platform in the current healthcare system. By doing so, medication adherence will improve, leading to healthier patients and lower healthcare costs.
VESPER Attorneys advised Health Innovation Fund III on this transaction.
For more info please refer to the press release (Dutch language).